EGFR Inhibitors as Host-directed Therapies for Tuberculosis
Tuberculosis is the leading cause of infectious disease death. During infection, macrophages phagocytose bacteria and either successfully control infection or become a niche for replication. Host-directed therapies (HDTs) improve macrophages’ control of infection. However, HDTs act via unclear mechanisms, and many HDT-induced antimicrobial responses are dispensable for control. Here, I describe ongoing work characterizing EGFR inhibitors as HDTs and defining their mechanisms of action.